Safety and efficacy of the surpass streamline for intracranial aneurysms (SESSIA): A multi-center US experience pooled analysis.
Intracranial aneurysm
flow diverter
interventional
subarachnoid hemorrhage
Journal
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
ISSN: 2385-2011
Titre abrégé: Interv Neuroradiol
Pays: United States
ID NLM: 9602695
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
pmc-release:
01
10
2024
medline:
23
10
2023
pubmed:
9
8
2022
entrez:
8
8
2022
Statut:
ppublish
Résumé
Flow diversion has established as standard treatment for intracranial aneurysms, the Surpass Streamline is the only FDA-approved braided cobalt/chromium alloy implant with 72-96 wires. We aimed to determine the safety and efficacy of the Surpass in a post-marketing large United States cohort. This is a retrospective multicenter study of consecutive patients treated with the Surpass for intracranial aneurysms between 2018 and 2021. Baseline demographics, comorbidities, and aneurysm characteristics were collected. Efficacy endpoint included aneurysm occlusion on radiographic follow-up. Safety endpoints were major ipsilateral ischemic stroke or treatment-related death. A total of 277 patients with 314 aneurysms were included. Median age was 60 years, 202 (73%) patients were females. Hypertension was the most common comorbidity in 156 (56%) patients. The most common location of the aneurysms was the anterior circulation in 89% (279/314). Mean aneurysm dome width was 5.77 ± 4.75 mm, neck width was 4.22 ± 3.83 mm, and dome/neck ratio was 1.63 ± 1.26. Small-sized aneurysms were 185 (59%). Single device was used in 94% of the patients, mean number of devices per patient was 1.06. At final follow-up, complete obliteration rate was 81% (194/239). Major stroke and death were encountered in 7 (3%) and 6 (2%) cases, respectively. This is the largest cohort study using a 72-96 wire flow diverter. The Surpass Streamline demonstrated a favorable safety and efficacy profile, making it a valuable option for treating not only large but also wide-necked small and medium-sized intracranial aneurysms.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Flow diversion has established as standard treatment for intracranial aneurysms, the Surpass Streamline is the only FDA-approved braided cobalt/chromium alloy implant with 72-96 wires. We aimed to determine the safety and efficacy of the Surpass in a post-marketing large United States cohort.
MATERIALS AND METHODS
METHODS
This is a retrospective multicenter study of consecutive patients treated with the Surpass for intracranial aneurysms between 2018 and 2021. Baseline demographics, comorbidities, and aneurysm characteristics were collected. Efficacy endpoint included aneurysm occlusion on radiographic follow-up. Safety endpoints were major ipsilateral ischemic stroke or treatment-related death.
RESULTS
RESULTS
A total of 277 patients with 314 aneurysms were included. Median age was 60 years, 202 (73%) patients were females. Hypertension was the most common comorbidity in 156 (56%) patients. The most common location of the aneurysms was the anterior circulation in 89% (279/314). Mean aneurysm dome width was 5.77 ± 4.75 mm, neck width was 4.22 ± 3.83 mm, and dome/neck ratio was 1.63 ± 1.26. Small-sized aneurysms were 185 (59%). Single device was used in 94% of the patients, mean number of devices per patient was 1.06. At final follow-up, complete obliteration rate was 81% (194/239). Major stroke and death were encountered in 7 (3%) and 6 (2%) cases, respectively.
CONCLUSION
CONCLUSIONS
This is the largest cohort study using a 72-96 wire flow diverter. The Surpass Streamline demonstrated a favorable safety and efficacy profile, making it a valuable option for treating not only large but also wide-necked small and medium-sized intracranial aneurysms.
Identifiants
pubmed: 35934939
doi: 10.1177/15910199221118148
pmc: PMC10549718
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
589-598Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM139776
Pays : United States
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Neurosurg. 2017 Dec;127(6):1333-1341
pubmed: 28059658
Stroke. 2009 Mar;40(3):952-8
pubmed: 19150864
Neurosurgery. 2013 Aug;73(2):193-9; discussion 199-200
pubmed: 23624409
Stroke. 2013 Jun;44(6):1567-77
pubmed: 23686973
J Neurosurg. 2018 Mar 30;130(1):259-267
pubmed: 29600915
World Neurosurg. 2022 May;161:e384-e394
pubmed: 35151920
J Neurointerv Surg. 2020 Jan;12(1):62-66
pubmed: 31308197
Hong Kong Med J. 2011 Oct;17(5):398-404
pubmed: 21979478
Neurosurgery. 1997 Dec;41(6):1235-45; discussion 1245-6
pubmed: 9402574
J Neurointerv Surg. 2021 Jan;13(1):54-62
pubmed: 32978269
J Neurol. 2015 Sep;262(9):2115-23
pubmed: 26100332
AJNR Am J Neuroradiol. 2015 Jan;36(1):98-107
pubmed: 25125666
J Neurointerv Surg. 2017 Jan;9(1):70-76
pubmed: 27439887
J Neurointerv Surg. 2022 Sep;14(9):898-903
pubmed: 34782399
Neuroradiology. 2022 Feb;64(2):343-351
pubmed: 34453182
Neurosurgery. 2018 Apr 1;82(4):491-496
pubmed: 28605486
Expert Rev Med Devices. 2014 Mar;11(2):137-50
pubmed: 24506298
Radiology. 2013 Jun;267(3):858-68
pubmed: 23418004
Lancet. 2003 Jul 12;362(9378):103-10
pubmed: 12867109
Stroke. 2013 Feb;44(2):442-7
pubmed: 23321438
J Neurosurg. 2017 Oct;127(4):775-780
pubmed: 27791519
Interv Neuroradiol. 2019 Jun;25(3):344-347
pubmed: 30486725
Stroke. 2019 Jun;50(6):1473-1479
pubmed: 31084335
AJNR Am J Neuroradiol. 2017 Dec;38(12):2295-2300
pubmed: 28912285
Interv Neurol. 2016 Jun;5(1-2):89-99
pubmed: 27610126
J Neurointerv Surg. 2018 Sep;10(9):843-850
pubmed: 29802165
AJNR Am J Neuroradiol. 2018 May;39(5):841-847
pubmed: 29545252
J Neurointerv Surg. 2019 Feb;11(2):184-189
pubmed: 30297539
Surg Neurol Int. 2021 Oct 06;12:506
pubmed: 34754556
Neuroradiology. 2012 Oct;54(10):1145-52
pubmed: 22569955
J Neurointerv Surg. 2019 Jul;11(7):690-693
pubmed: 30514737
AJNR Am J Neuroradiol. 2015 Jan;36(1):108-15
pubmed: 25355814